Serial cross-sectional seroprevalence study of SARS-CoV-2 infection during and after the COVID-19 epidemic in Heidelberg and the Rhein-Neckar regio

• Conditions: SARS-CoV-2 infection; U07.1; COVID-19, virus identified

• Registration Number: DRKS00021709
• Lead Sponsor: niversita¨tsklinikum Heidelberg, Sektion Klinische Tropenmedizin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-05-18
• Study Completion: 2020-11-11
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting stopped after recruiting started
• Sex: All
• Target Recruitment: 1283

Inclusion Criteria

a) Able to provide a blood sample
b) Able to attend the Tropical Medicine clinic for blood draw or be available for a house visit
c) In adults, the ability to provide fully informed consent
d) Consent from a parent or guardian if the patient is under 18

Exclusion Criteria

a) Contraindication to venepuncture
b) Age below 5 years of age
c) Not able to provide informed consent

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Age-group specific prevalence of antibodies to SARS-CoV-2 among the general population of Heidelberg and the Rhein-Neckar region.

Secondary Outcome Measures

Name	Time	Method
1) Age-group specific cumulative incidence during the epidemic compared to the end of the epidemic (post-epidemic) or according to local COVID-19 epidemiology.<br>2) Association of risk factors / protective measures recorded on the questionnaire and evidence of SARS-CoV-2 infection (SARS-CoV-2 antibodies).<br>3) Proportion of asymptomatic / sub-clinical SARS-CoV-2 infections.<br>